Afonja et al. treated T-47D and MCF-7 breast cancer cells with Am580 (a selective RARα agonist) and all-trans retinoic acid (ATRA, another RAR agonist derived from vitamin A retinoids) and found that PDCD4 expression was increased two- to five-fold. Here, RARA is linked to breast cancer.